TriSalus Life Sciences Inc. Market Cap ($200.12 Million)
Market Cap & Net Worth: TriSalus Life Sciences Inc. (TLSI)
TriSalus Life Sciences Inc. market cap. TriSalus Life Sciences Inc. (NASDAQ:TLSI) has a market capitalization of $200.12 Million ($200.12 Million) as of November 8, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16299 globally and #3886 in its home market, demonstrating a -15.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TriSalus Life Sciences Inc.'s stock price $3.25 by its total outstanding shares 61574600 (61.57 Million). Also see TriSalus Life Sciences Inc. cash conversion from operations for how efficiently the company converts equity into cash flow.
TriSalus Life Sciences Inc. Market Cap History (2021–2026)
TriSalus Life Sciences Inc. market cap history from 2021 to 2026. Data shows change from $608.36 Million to $200.12 Million (-18.49% CAGR). Check TriSalus Life Sciences Inc. stock quote for real-time trading data and today's change.
Index Memberships
TriSalus Life Sciences Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.01% | #439 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.00% | #1594 of 3165 |
Weight: TriSalus Life Sciences Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TriSalus Life Sciences Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TriSalus Life Sciences Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore TriSalus Life Sciences Inc. (TLSI) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.52x
TriSalus Life Sciences Inc.'s market cap is 9.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $608.36 Million | $8.40 Million | -$28.84 Million | 72.41x | N/A |
| 2022 | $617.59 Million | $12.40 Million | -$47.19 Million | 49.81x | N/A |
| 2023 | $520.31 Million | $18.51 Million | -$59.36 Million | 28.11x | N/A |
| 2024 | $308.49 Million | $29.43 Million | -$33.23 Million | 10.48x | N/A |
| 2025 | $429.79 Million | $45.15 Million | -$39.23 Million | 9.52x | N/A |
Competitor Companies of TLSI by Market Capitalization
Companies near TriSalus Life Sciences Inc. in the global market cap rankings as of November 8, 2026. Also see TriSalus Life Sciences Inc. balance sheet assets for a full breakdown of the balance sheet.
Key companies related to TriSalus Life Sciences Inc. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #109 globally with a market cap of $191.15 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #188 globally with a market cap of $124.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #222 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #109 | Abbott Laboratories | NYSE:ABT | $191.15 Billion | $109.93 |
| #188 | Stryker Corporation | NYSE:SYK | $124.99 Billion | $325.87 |
| #222 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $101.80 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of TriSalus Life Sciences Inc. (2021–2026)
Market capitalization of TriSalus Life Sciences Inc. from 2021 to today. Between 2021 and today, TriSalus Life Sciences Inc.'s market cap moved from $608.36 Million to $ 200.12 Million, with a yearly change of -18.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $200.12 Million | -53.44% |
| 2025 | $429.79 Million | +39.32% |
| 2024 | $308.49 Million | -40.71% |
| 2023 | $520.31 Million | -15.75% |
| 2022 | $617.59 Million | +1.52% |
| 2021 | $608.36 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of TriSalus Life Sciences Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $200.12 Million USD |
| MoneyControl | $200.12 Million USD |
| MarketWatch | $200.12 Million USD |
| marketcap.company | $200.12 Million USD |
| Reuters | $200.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial… Read more